GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (FRA:2F5) » Definitions » Effective Interest Rate on Debt %

Scinai Immunotherapeutics (FRA:2F5) Effective Interest Rate on Debt % : 66.38% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scinai Immunotherapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Scinai Immunotherapeutics's annualized positive value of Interest Expense for the quarter that ended in Sep. 2024 was €6.79 Mil. Scinai Immunotherapeutics's average total debt for the quarter that ended in Sep. 2024 was €10.23 Mil. Therefore, Scinai Immunotherapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2024 was 66.38%.


Scinai Immunotherapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Scinai Immunotherapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Effective Interest Rate on Debt % Chart

Scinai Immunotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.81 1.12 14.41 0.09 0.04

Scinai Immunotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.15 4.50 5.72 66.38

Competitive Comparison of Scinai Immunotherapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Scinai Immunotherapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Effective Interest Rate on Debt % falls into.



Scinai Immunotherapeutics Effective Interest Rate on Debt % Calculation

Scinai Immunotherapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -0.008/( (20.336+18.854)/ 2 )
=-1  *  -0.008/19.595
=0.04 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=19.975 + 0.361
=20.336

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=18.491 + 0.363
=18.854

Scinai Immunotherapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2024 )+Total Debt  (Q: Sep. 2024 ))/ count )
=-1  *  -6.788/( (19.345+1.106)/ 2 )
=-1  *  -6.788/10.2255
=66.38 %

where

Total Debt  (Q: Jun. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=19.007 + 0.338
=19.345

Total Debt  (Q: Sep. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.778 + 0.328
=1.106

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Scinai Immunotherapeutics  (FRA:2F5) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Scinai Immunotherapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Scinai Immunotherapeutics Headlines

No Headlines